Endocrine-Related Cancer
@endocancer.bsky.social
Publishing translational & clinical investigations of human health & disease focusing on #endocrine neoplasias & hormone-dependent #cancers. Owned by Society of Endocrinology.
Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
November 13, 2025 at 12:54 PM
Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
November 11, 2025 at 12:20 PM
🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
November 10, 2025 at 12:49 PM
Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
November 5, 2025 at 8:18 AM
We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
October 29, 2025 at 9:31 AM
Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
October 21, 2025 at 9:03 AM
🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Early-Career Editor Opening!
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
October 17, 2025 at 8:58 AM
Early-Career Editor Opening!
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
September 30, 2025 at 8:24 AM
New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
September 25, 2025 at 9:00 AM
New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
September 24, 2025 at 7:39 AM
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
September 16, 2025 at 9:53 AM
🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
September 9, 2025 at 1:44 PM
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
September 5, 2025 at 3:07 PM
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
September 3, 2025 at 7:42 AM
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
🌱Endocrine-Related Cancer is officially on LinkedIn!
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
August 29, 2025 at 10:31 AM
🌱Endocrine-Related Cancer is officially on LinkedIn!
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.
🌐 linkedin.com/company/endocrine-related-cancer/
#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
✨ Systems biology approaches are reshaping our understanding of cancer.
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
August 26, 2025 at 8:11 AM
✨ Systems biology approaches are reshaping our understanding of cancer.
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
Latest review by Michael V Orman et al. (@cupharmacology.bsky.social) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.
👉 #OpenAccess - doi.org/10.1530/ERC-25-0067
🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at Griffith University, has joined Endocrine-Related Cancer's editorial board as an Associate Editor.
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
August 20, 2025 at 8:34 AM
🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at Griffith University, has joined Endocrine-Related Cancer's editorial board as an Associate Editor.
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
August 18, 2025 at 9:10 AM
Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
Learn more: mierf.org/to-apply/
#neuroendocrinecancer #earlycareerresearcher
🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy?
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
August 12, 2025 at 8:16 AM
🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy?
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.
🔗Explore the results: doi.org/10.1530/ERC-25-0031
How do treatments for neuroendocrine neoplasms impact quality of life?
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
August 7, 2025 at 10:19 AM
How do treatments for neuroendocrine neoplasms impact quality of life?
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.
📖 Read more: doi.org/10.1530/ERC-24-0303
✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer!
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
July 29, 2025 at 10:20 AM
✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer!
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
Dr. Pacak's term begins on 1st January 2026.
We are excited for this next chapter, driven by his expertise and vision 🚀
🧪New research by Jinheng Xiao et al. explores the distinct metabolic profiles of parathyroid carcinoma and parathyroid adenoma, identifying promising biomarkers for preoperative diagnosis of parathyroid carcinoma.
Read the full article #OpenAccess: doi.org/10.1530/ERC-24-0192
Read the full article #OpenAccess: doi.org/10.1530/ERC-24-0192
July 21, 2025 at 9:23 AM
🧪New research by Jinheng Xiao et al. explores the distinct metabolic profiles of parathyroid carcinoma and parathyroid adenoma, identifying promising biomarkers for preoperative diagnosis of parathyroid carcinoma.
Read the full article #OpenAccess: doi.org/10.1530/ERC-24-0192
Read the full article #OpenAccess: doi.org/10.1530/ERC-24-0192
Attending #ENDO2025? Come and visit the Bioscientifica booth, 803, to learn more about publishing in Endocrine-Related Cancer and pick up a booklet of recently published research 🤩🙌
July 12, 2025 at 11:13 PM
Attending #ENDO2025? Come and visit the Bioscientifica booth, 803, to learn more about publishing in Endocrine-Related Cancer and pick up a booklet of recently published research 🤩🙌
🧬New research by Mina Sattari et al. identifies 85 metastatic castration-resistant prostate cancer-associated genes, spotlighting TMEM18 as a promising prognostic biomarker in early prostate cancer.
👉 Explore the full article #OpenAccess: doi.org/10.1530/ERC-25-0070
👉 Explore the full article #OpenAccess: doi.org/10.1530/ERC-25-0070
July 3, 2025 at 10:10 AM
🧬New research by Mina Sattari et al. identifies 85 metastatic castration-resistant prostate cancer-associated genes, spotlighting TMEM18 as a promising prognostic biomarker in early prostate cancer.
👉 Explore the full article #OpenAccess: doi.org/10.1530/ERC-25-0070
👉 Explore the full article #OpenAccess: doi.org/10.1530/ERC-25-0070
👋We are thrilled to join the @bsky.app community!
We spotlight novel research on endocrine neoplasias & hormone-dependent cancers.
Follow us for the latest articles, themed collections & developments in endocrine oncology.
🧬Explore: erc.bioscientifica.com
We spotlight novel research on endocrine neoplasias & hormone-dependent cancers.
Follow us for the latest articles, themed collections & developments in endocrine oncology.
🧬Explore: erc.bioscientifica.com
June 27, 2025 at 8:22 AM
👋We are thrilled to join the @bsky.app community!
We spotlight novel research on endocrine neoplasias & hormone-dependent cancers.
Follow us for the latest articles, themed collections & developments in endocrine oncology.
🧬Explore: erc.bioscientifica.com
We spotlight novel research on endocrine neoplasias & hormone-dependent cancers.
Follow us for the latest articles, themed collections & developments in endocrine oncology.
🧬Explore: erc.bioscientifica.com